Physician profile
Robert N Brady
NPI 1629653530
$1,173.84
in general payments reported to CMS, 2019-2025
15 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.81 · 2022: $444 · 2023: $103 · 2024: $244 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.48 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $221.85 | 2022-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.90 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $104.74 | 2022-2025 | |
| Ultragenyx Pharmaceutical INC. | $74.63 | 2022 | |
| Supernus Pharmaceuticals, INC. | $66.88 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $66.72 | 2024-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $47.91 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $45.36 | 2022-2023 | Trintellix |
| Alkermes, INC. | $40.17 | 2022-2023 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $33.82 | 2024 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $30.65 | 2021 | |
| Vanda Pharmaceuticals INC. | $30.21 | 2022-2023 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $24.83 | 2025 | Auvelity |
| Lundbeck LLC | $14.69 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.